Invention Grant
- Patent Title: Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
-
Application No.: US15521199Application Date: 2015-10-21
-
Publication No.: US10023576B2Publication Date: 2018-07-17
- Inventor: Rajeev S. Bhide , Zheming Ruan , Robert J. Cherney , Lyndon A. M. Cornelius , T. G. Murali Dhar , Hua Gong , David Marcoux , Michael A. Poss , Lan-ying Qin , Qing Shi , Joseph A. Tino
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Gary Greenblatt
- International Application: PCT/US2015/056577 WO 20151021
- International Announcement: WO2016/064958 WO 20160428
- Main IPC: C07D487/04
- IPC: C07D487/04

Abstract:
Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, —CN, —CH3, or —CF3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R1; Q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with R2 and R3; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.
Public/Granted literature
- US20170355698A1 HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS Public/Granted day:2017-12-14
Information query